Discover
ORKA
Oruka Therapeutics, Inc.
103.18
1 x 103.10
1 x 103.27
bid
ask
-
1.96
1.86%
12:33 PM
timesize
| Ytd | 240.42% | |
| 1y | 690.65% |
102.33
day range
107.55
13.06
52 week range
107.55
| Open | 106.78 | Prev Close | 105.14 | Low | 102.33 | High | 107.55 | Mkt Cap | 6.22B |
| Vol | 133.83K | Avg Vol | 1.30M | EPS | -1.94 | P/E | -53.19 | Forward P/E | -39.65 |
| Beta | -0.34 | Short Ratio | 4.99 | Inst. Own | 103.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 82.71 | 200-d Avg | 51.16 | 1yr Est | 148.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-18 | 2026-09 | -0.57 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.51 | -0.55 | -0.04 | -7.32% |
| 2026-05-13 | 2026-03 | -0.55 | -0.48 | 0.07 | 12.24% |
| 2026-03-12 | 2025-12 | -0.61 | -0.45 | 0.16 | 26.23% |
| 2025-11-12 | 2025-09 | -0.56 | -0.55 | 0.01 | 1.79% |
| 2025-08-11 | 2025-06 | -0.48 | -0.46 | 0.02 | 4.17% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-13 | BTIG | Upgrade | Buy | Buy |
| 2026-07-01 | UBS | Upgrade | Buy | Buy |
| 2026-06-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | BTIG | Upgrade | Buy | Buy |
Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-07-12 | AGARWAL ARJUN | Officer | 15.31K | Sale |
| 2026-06-11 | DAMBKOWSKI CARL | Director | 38.74K | Sale |
| 2026-06-30 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-07-14 | GONCALVES JOANA | Officer | 32.72K | Sale |
| 2024-08-15 | JANUS HENDERSON GROUP PLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-14 | KLEIN LAWRENCE OTTO | Chief Executive Officer | 925.58K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 7.43M | 734.37M | 12.32% |
| 2026-06-29 | Blackrock Inc. | 4.99M | 493.13M | 8.27% |
| 2026-03-30 | Venrock Adviser, LLC | 4.15M | 409.95M | 6.88% |
| 2026-03-30 | Fairmount Funds Management LLC | 3.71M | 366.15M | 6.14% |
| 2026-06-29 | State Street Corporation | 2.67M | 264.15M | 4.43% |
| 2026-03-30 | Viking Global Investors, L.P. | 2.67M | 263.52M | 4.42% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.55M | 153.10M | 2.57% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 135.85M | 2.28% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.32M | 130.37M | 2.19% |
| 2026-06-29 | New Economy Fund | 1.32M | 130.77M | 2.19% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.26M | 124.56M | 2.09% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 835.50K | 82.56M | 1.39% |
Dividend
| Dividend | Date |
|---|---|
| 1.613 | 2024-08-29 |